中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2015年
17期
18-19
,共2页
廖纪华%郑乃清%唐锦程%吴新爱
廖紀華%鄭迺清%唐錦程%吳新愛
료기화%정내청%당금정%오신애
急性腔隙性脑梗死%长春西汀%依达拉奉
急性腔隙性腦梗死%長春西汀%依達拉奉
급성강극성뇌경사%장춘서정%의체랍봉
Acute lacunar infarction%Vinpocetine%Edaravone
目的:观察长春西汀注射液联合依达拉奉治疗急性腔隙性脑梗死的临床疗效。方法96例急性腔隙性脑梗死患者随机分为观察组和对照组,各48例,两组在治疗相应基础病和常规抗凝、抗血小板聚集治疗基础上,观察组加用长春西汀注射液及依达拉奉进行治疗,对照组加用倍他司汀注射液及血塞通注射液进行治疗,疗程2周。观察两组治疗效果、记录不良反应、评估安全性。治疗前和治疗2周后进行欧洲脑卒中评分(ESS),用积分评判疗效。结果观察组总有效率为93.8%,优于对照组81.3%,差异具有统计学意义(P<0.05)。两组药物无明显不良反应。结论相比使用倍他司汀+血塞通,长春西汀联合依达拉奉治疗急性腔隙性脑梗死疗效确切,安全性好,值得临床推广应用。
目的:觀察長春西汀註射液聯閤依達拉奉治療急性腔隙性腦梗死的臨床療效。方法96例急性腔隙性腦梗死患者隨機分為觀察組和對照組,各48例,兩組在治療相應基礎病和常規抗凝、抗血小闆聚集治療基礎上,觀察組加用長春西汀註射液及依達拉奉進行治療,對照組加用倍他司汀註射液及血塞通註射液進行治療,療程2週。觀察兩組治療效果、記錄不良反應、評估安全性。治療前和治療2週後進行歐洲腦卒中評分(ESS),用積分評判療效。結果觀察組總有效率為93.8%,優于對照組81.3%,差異具有統計學意義(P<0.05)。兩組藥物無明顯不良反應。結論相比使用倍他司汀+血塞通,長春西汀聯閤依達拉奉治療急性腔隙性腦梗死療效確切,安全性好,值得臨床推廣應用。
목적:관찰장춘서정주사액연합의체랍봉치료급성강극성뇌경사적림상료효。방법96례급성강극성뇌경사환자수궤분위관찰조화대조조,각48례,량조재치료상응기출병화상규항응、항혈소판취집치료기출상,관찰조가용장춘서정주사액급의체랍봉진행치료,대조조가용배타사정주사액급혈새통주사액진행치료,료정2주。관찰량조치료효과、기록불량반응、평고안전성。치료전화치료2주후진행구주뇌졸중평분(ESS),용적분평판료효。결과관찰조총유효솔위93.8%,우우대조조81.3%,차이구유통계학의의(P<0.05)。량조약물무명현불량반응。결론상비사용배타사정+혈새통,장춘서정연합의체랍봉치료급성강극성뇌경사료효학절,안전성호,치득림상추엄응용。
Objective To investigate the clinical effect of vinpocetine combined with edaravone in the treatment of acute lacunar infarction.Methods A total of 96 acute lacunar infarction patients were randomly divided into observation group and control group, with 48 cases in each group. On the basis of treatment for background disease, conventional anticoagulation, and anti-platelet aggregation, the observation group received vinpocetine injection combined with edaravone for treatment, and the control group received betahistine injection and Xuesaitong injection for treatment. Treatment lasted for 2 weeks. Curative effects of the two groups were observed, their adverse reactions were recorded and safety was evaluated. The European stroke scale (ESS) was applied before treatment and in 2 weeks after treatment, and their scores were used for effects evaluation.ResultsTotal effective rate of the observation group was 93.8%, which was much better than 81.3% of the control group. The difference had statistical significance (P<0.05). Both groups had no obvious adverse reactions.Conclusion Compared with betahistine + Xuesaitong, the combination of vinpocetine and edaravone provides precise effect and good safety in treating acute lacunar infarction. This method is worthy of clinical promotion and application.